Home / Publications / Анализ подходов связывания прямого панселективного ингибирования мутантных форм гуанозинтрифосфатазы KRAS и перспективы таргетирования различных аллостерических сайтов

Анализ подходов связывания прямого панселективного ингибирования мутантных форм гуанозинтрифосфатазы KRAS и перспективы таргетирования различных аллостерических сайтов

Д. О. Шкиль 1 *
Д. О. Шкиль
И. А. Елисеев 2
И. А. Елисеев
К. В. Балакин 1
К. В. Балакин
Published 2025-12-10
Share
Cite this
GOST
 | 
Cite this
GOST Copy
Шкиль Д. О. et al. Анализ подходов связывания прямого панселективного ингибирования мутантных форм гуанозинтрифосфатазы KRAS и перспективы таргетирования различных аллостерических сайтов // Russian Chemical Bulletin. 2025. Vol. 75. No. 1. pp. 51-72.
GOST all authors (up to 50) Copy
Шкиль Д. О., Елисеев И. А., Иванов Р. А., Балакин К. В. Анализ подходов связывания прямого панселективного ингибирования мутантных форм гуанозинтрифосфатазы KRAS и перспективы таргетирования различных аллостерических сайтов // Russian Chemical Bulletin. 2025. Vol. 75. No. 1. pp. 51-72.
RIS
 | 
Cite this
RIS Copy
TY - JOUR
UR - https://russchembull.colab.ws/publications/32
TI - Анализ подходов связывания прямого панселективного ингибирования мутантных форм гуанозинтрифосфатазы KRAS и перспективы таргетирования различных аллостерических сайтов
T2 - Russian Chemical Bulletin
AU - Шкиль, Д. О.
AU - Елисеев, И. А.
AU - Иванов, Р. А.
AU - Балакин, К. В.
PY - 2025
DA - 2025/12/10
PB - Известия Академии наук. Серия химическая
SP - 51-72
IS - 1
VL - 75
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors) Copy
@article{2025_Шкиль,
author = {Д. О. Шкиль and И. А. Елисеев and Р. А. Иванов and К. В. Балакин},
title = {Анализ подходов связывания прямого панселективного ингибирования мутантных форм гуанозинтрифосфатазы KRAS и перспективы таргетирования различных аллостерических сайтов},
journal = {Russian Chemical Bulletin},
year = {2025},
volume = {75},
publisher = {Известия Академии наук. Серия химическая},
month = {Dec},
url = {https://russchembull.colab.ws/publications/32},
number = {1},
pages = {51--72}
}
MLA
Cite this
MLA Copy
Шкиль, Д. О., et al. “Анализ подходов связывания прямого панселективного ингибирования мутантных форм гуанозинтрифосфатазы KRAS и перспективы таргетирования различных аллостерических сайтов.” Russian Chemical Bulletin, vol. 75, no. 1, Dec. 2025, pp. 51-72. https://russchembull.colab.ws/publications/32.

Keywords

KRAS
аллостерическое ингибирование
дизайн лекарств
молекулярное моделирование
панселективность
рак легкого

Abstract

Представлен подробный обзор последних достижений в разработке ингибиторов мутантных форм гуанозинтрифосфатазы KRAS, которая играет ключевую роль в патогенезе различных онкологических заболеваний. Сделан акцент на сложности и ограничениях таргетирования KRAS из-за его структурных особенностей и высокой частоты мутаций. Основное внимание уделено панселективным ингибиторам, способным действовать на несколько различных мутаций KRAS, что важно для преодоления резистентности опухолей к терапии. Приведены примеры перспективных молекулярных структур, анализ механизмов действия и возможных причин селективности.

References

2.
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?
Vigil D., Cherfils J., Rossman K.L., Der C.J.
Nature Reviews Cancer, 2010
3.
RAS oncogenes: the first 30 years
Malumbres M., Barbacid M.
Nature Reviews Cancer, 2003
4.
Targeting RAS signalling pathways in cancer therapy
5.
RAS-targeted therapies: is the undruggable drugged?
Moore A.R., Rosenberg S.C., McCormick F., Malek S.
Nature Reviews Drug Discovery, 2020
7.
KRAS mutation: from undruggable to druggable in cancer
Huang L., Guo Z., Wang F., Fu L.
Signal Transduction and Targeted Therapy, 2021
9.
Expression, purification, and characterization of soluble K-Ras4B for structural analysis
Abraham S.J., Muhamed I., Nolet R., Yeung F., Gaponenko V.
Protein Expression and Purification, 2010
10.
Structural insights into isoform-specific RAS-PI3Kα interactions and the role of RAS in PI3Kα activation
Czyzyk D., Yan W., Messing S., Gillette W., Tsuji T., Yamaguchi M., Furuzono S., Turner D.M., Esposito D., Nissley D.V., McCormick F., Simanshu D.K.
Nature Communications, 2025
11.
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Kwan A.K., Piazza G.A., Keeton A.B., Leite C.A.
Journal of Experimental and Clinical Cancer Research, 2022
12.
Drugging the 'undruggable' cancer targets
Dang C.V., Reddy E.P., Shokat K.M., Soucek L.
Nature Reviews Cancer, 2017
13.
Farnesyl Transferase Inhibitors as Potential Anticancer Agents
Bagchi S., Rathee P., Jayaprakash V., Banerjee S.
Mini-Reviews in Medicinal Chemistry, 2018
14.
Intrinsic protein disorder in oncogenic KRAS signaling
Nussinov R., Jang H., Tsai C., Liao T., Li S., Fushman D., Zhang J.
Cellular and Molecular Life Sciences, 2017
15.
Rce1: mechanism and inhibition
Hampton S.E., Dore T.M., Schmidt W.K.
Critical Reviews in Biochemistry and Molecular Biology, 2018
16.
Atomic structure of the eukaryotic intramembrane RAS methyltransferase ICMT
Diver M.M., Pedi L., Koide A., Koide S., Long S.B.
Nature, 2018
17.
Perspectives on farnesyl transferase inhibitors in cancer therapy
18.
K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors*
Whyte D.B., Kirschmeier P., Hockenberry T.N., Nunez-Oliva I., James L., Catino J.J., Bishop W.R., Pai J.
Journal of Biological Chemistry, 1997
19.
Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression
Court H., Amoyel M., Hackman M., Lee K.E., Xu R., Miller G., Bar-Sagi D., Bach E.A., Bergö M.O., Philips M.R.
Journal of Clinical Investigation, 2013
20.
Rce1 deficiency accelerates the development of K-RAS–induced myeloproliferative disease
Wahlstrom A.M., Cutts B.A., Karlsson C., Andersson K.M., Liu M., Sjogren A.M., Swolin B., Young S.G., Bergo M.O.
Blood, 2006
21.
A12 The SHP2 Inhibitor RMC-4630 in Patients with KRAS-Mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-Man Phase 1 Clinical Trial
Ou S.I., Koczywas M., Ulahannan S., Janne P., Pacheco J., Burris H., McCoach C., Wang J.S., Gordon M., Haura E., Riess J.W., Zhu V., Ng K., Eckhardt S.G., Capasso A., et. al.
Journal of Thoracic Oncology, 2020
22.
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
Nichols R.J., Haderk F., Stahlhut C., Schulze C.J., Hemmati G., Wildes D., Tzitzilonis C., Mordec K., Marquez A., Romero J., Hsieh T., Zaman A., Olivas V., McCoach C., Blakely C.M., et. al.
Nature Cell Biology, 2018
23.
BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Hofmann M.H., Gmachl M., Ramharter J., Savarese F., Gerlach D., Marszalek J.R., Sanderson M.P., Kessler D., Trapani F., Arnhof H., Rumpel K., Botesteanu D., Ettmayer P., Gerstberger T., Kofink C., et. al.
Cancer Discovery, 2021
24.
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
Zhu C., Guan X., Zhang X., Luan X., Song Z., Cheng X., Zhang W., Qin J.
Molecular Cancer, 2022
25.
Tumor adaptation and resistance to RAF inhibitors
Lito P., Rosen N., Solit D.B.
Nature Medicine, 2013
26.
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
Desai J., Gan H., Barrow C., Jameson M., Atkinson V., Haydon A., Millward M., Begbie S., Brown M., Markman B., Patterson W., Hill A., Horvath L., Nagrial A., Richardson G., et. al.
Journal of Clinical Oncology, 2020
27.
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
28.
KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC
Niemantsverdriet M., Schuuring E., Elst A.T., van der Wekken A.J., van Kempen L.C., van den Berg A., Groen H.J.
Journal of Thoracic Oncology, 2018
30.
ERK5 Signalling and Resistance to ERK1/2 Pathway Therapeutics: The Path Less Travelled?
Cook S.J., Lochhead P.A.
Frontiers in Cell and Developmental Biology, 2022
31.
The Frequency of Ras Mutations in Cancer
Prior I.A., Hood F.E., Hartley J.L.
Cancer Research, 2020
32.
AACR Project GENIE: Powering Precision Medicine through an International Consortium
André F., Arnedos M., Baras A.S., Baselga J., Bedard P.L., Berger M.F., Bierkens M., Calvo F., Cerami E., Chakravarty D., Dang K.K., Davidson N.E., Del Vecchio Fitz C., Dogan S., DuBois R.N., et. al.
Cancer Discovery, 2017
33.
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem J.M., Peters U., Sos M.L., Wells J.A., Shokat K.M.
Nature, 2013
34.
Covalent inhibitors of the GTPase KRASG12C: a review of the patent literature
Kettle J.G., Cassar D.J.
Expert Opinion on Therapeutic Patents, 2020
35.
Inhibitors of the GTPase KRASG12C in cancer: a patent review (2019-2021)
Xu Q., Zhang G., Liu Q., Li S., Zhang Y.
Expert Opinion on Therapeutic Patents, 2022
36.
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
Fell J.B., Fischer J.P., Baer B.R., Blake J.F., Bouhana K., Briere D.M., Brown K.D., Burgess L.E., Burns A.C., Burkard M.R., Chiang H., Chicarelli M.J., Cook A.W., Gaudino J.J., Hallin J., et. al.
Journal of Medicinal Chemistry, 2020
37.
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
Lanman B.A., Allen J.R., Allen J.G., Amegadzie A.K., Ashton K.S., Booker S.K., Chen J.J., Chen N., Frohn M.J., Goodman G., Kopecky D.J., Liu L., Lopez P., Low J.D., Ma V., et. al.
Journal of Medicinal Chemistry, 2019
40.
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Nagasaka M., Li Y., Sukari A., Ou S.I., Al-Hallak M.N., Azmi A.S.
Cancer Treatment Reviews, 2020
42.
Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D
Zheng Q., Zhang Z., Guiley K.Z., Shokat K.M.
Nature Chemical Biology, 2024
43.
Chemoselective Covalent Modification of K-Ras(G12R) with a Small Molecule Electrophile
Zhang Z., Morstein J., Ecker A.K., Guiley K.Z., Shokat K.M.
Journal of the American Chemical Society, 2022
45.
Simultaneous Covalent Modification of K-Ras(G12D) and K-Ras(G12C) with Tunable Oxirane Electrophiles
Yu Z., He X., Wang R., Xu X., Zhang Z., Ding K., Zhang Z., Tan Y., Li Z.
Journal of the American Chemical Society, 2023
46.
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer
Di Federico A., Ricciotti I., Favorito V., Michelina S.V., Scaparone P., Metro G., De Giglio A., Pecci F., Lamberti G., Ambrogio C., Ricciuti B.
Current Oncology Reports, 2023
47.
Acquired Resistance to KRASG12C Inhibition in Cancer
Awad M.M., Liu S., Rybkin I.I., Arbour K.C., Dilly J., Zhu V.W., Johnson M.L., Heist R.S., Patil T., Riely G.J., Jacobson J.O., Yang X., Persky N.S., Root D.E., Lowder K.E., et. al.
New England Journal of Medicine, 2021
48.
The KRAS-G12C inhibitor: activity and resistance
Liu J., Kang R., Tang D.
Cancer Gene Therapy, 2021
49.
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor
Wang X., Allen S., Blake J.F., Bowcut V., Briere D.M., Calinisan A., Dahlke J.R., Fell J.B., Fischer J.P., Gunn R.J., Hallin J., Laguer J., Lawson J.D., Medwid J., Newhouse B., et. al.
Journal of Medicinal Chemistry, 2021
50.
KRAS is vulnerable to reversible switch-II pocket engagement in cells
Vasta J.D., Peacock D.M., Zheng Q., Walker J.A., Zhang Z., Zimprich C.A., Thomas M.R., Beck M.T., Binkowski B.F., Corona C.R., Robers M.B., Shokat K.M.
Nature Chemical Biology, 2022
51.
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Hallin J., Bowcut V., Calinisan A., Briere D.M., Hargis L., Engstrom L.D., Laguer J., Medwid J., Vanderpool D., Lifset E., Trinh D., Hoffman N., Wang X., David Lawson J., Gunn R.J., et. al.
Nature Medicine, 2022
54.
KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge
Mao Z., Xiao H., Shen P., Yang Y., Xue J., Yang Y., Shang Y., Zhang L., Li X., Zhang Y., Du Y., Chen C., Guo R., Zhang Y.
Cell Discovery, 2022
55.
The current understanding of KRAS protein structure and dynamics
Pantsar T.
Computational and Structural Biotechnology Journal, 2020
56.
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
Kim D., Herdeis L., Rudolph D., Zhao Y., Böttcher J., Vides A., Ayala-Santos C.I., Pourfarjam Y., Cuevas-Navarro A., Xue J.Y., Mantoulidis A., Bröker J., Wunberg T., Schaaf O., Popow J., et. al.
Nature, 2023
57.
Multivalent Small-Molecule Pan-RAS Inhibitors
Welsch M.E., Kaplan A., Chambers J.M., Stokes M.E., Bos P.H., Zask A., Zhang Y., Sanchez-Martin M., Badgley M.A., Huang C.S., Tran T.H., Akkiraju H., Brown L.M., Nandakumar R., Cremers S., et. al.
Cell, 2017
58.
Discovery of High-Affinity Noncovalent Allosteric KRAS Inhibitors That Disrupt Effector Binding
McCarthy M.J., Pagba C.V., Prakash P., Naji A.K., van der Hoeven D., Liang H., Gupta A.K., Zhou Y., Cho K., Hancock J.F., Gorfe A.A.
ACS Omega, 2019
59.
Drugging an undruggable pocket on KRAS
Kessler D., Gmachl M., Mantoulidis A., Martin L.J., Zoephel A., Mayer M., Gollner A., Covini D., Fischer S., Gerstberger T., Gmaschitz T., Goodwin C., Greb P., Häring D., Hela W., et. al.
Proceedings of the National Academy of Sciences of the United States of America, 2019
60.
Reply to Tran et al.: Dimeric KRAS protein–protein interaction stabilizers
Kessler D., Gollner A., Gmachl M., Mantoulidis A., Martin L.J., Zoephel A., Mayer M., Covini D., Fischer S., Gerstberger T., Gmaschitz T., Goodwin C., Greb P., Häring D., Hela W., et. al.
Proceedings of the National Academy of Sciences of the United States of America, 2020
61.
K-RasG12D Has a Potential Allosteric Small Molecule Binding Site
Feng H., Zhang Y., Bos P.H., Chambers J.M., Dupont M.M., Stockwell B.R.
Biochemistry, 2019
63.
Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
Quevedo C.E., Cruz-Migoni A., Bery N., Miller A., Tanaka T., Petch D., Bataille C.J., Lee L.Y., Fallon P.S., Tulmin H., Ehebauer M.T., Fernandez-Fuentes N., Russell A.J., Carr S.B., Phillips S.E., et. al.
Nature Communications, 2018
64.
GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf
Zhang Z., Gao R., Hu Q., Peacock H., Peacock D.M., Dai S., Shokat K.M., Suga H.
ACS Central Science, 2020
65.
Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor
Tanada M., Tamiya M., Matsuo A., Chiyoda A., Takano K., Ito T., Irie M., Kotake T., Takeyama R., Kawada H., Hayashi R., Ishikawa S., Nomura K., Furuichi N., Morita Y., et. al.
Journal of the American Chemical Society, 2023
66.
FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC
Nakajima E.C., Drezner N., Li X., Mishra-Kalyani P.S., Liu Y., Zhao H., Bi Y., Liu J., Rahman A., Wearne E., Ojofeitimi I., Hotaki L.T., Spillman D., Pazdur R., Beaver J.A., et. al.
Clinical Cancer Research, 2021
68.
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
Schulze C.J., Seamon K.J., Zhao Y., Yang Y.C., Cregg J., Kim D., Tomlinson A., Choy T.J., Wang Z., Sang B., Pourfarjam Y., Lucas J., Cuevas-Navarro A., Ayala-Santos C., Vides A., et. al.
Science, 2023
69.
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Jiang J., Jiang L., Maldonato B.J., Wang Y., Holderfield M., Aronchik I., Winters I.P., Salman Z., Blaj C., Menard M., Brodbeck J., Chen Z., Wei X., Rosen M.J., Gindin Y., et. al.
Cancer Discovery, 2024
70.
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Holderfield M., Lee B.J., Jiang J., Tomlinson A., Seamon K.J., Mira A., Patrucco E., Goodhart G., Dilly J., Gindin Y., Dinglasan N., Wang Y., Lai L.P., Cai S., Jiang L., et. al.
Nature, 2024
71.
Analysis of Pan-Specific Inhibitors of Oncogenic Mutant Forms of KRAS GTPase
Eliseev I.A., Shkil D.O., Shumakova V.S., Chernyshov V.V., Balakin K.V., Ivanov R.A.
Current Medicinal Chemistry, 2025